ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0834

Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Abstract Number: 0835

Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
Abstract Number: 0836

SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus
Abstract Number: 0837

Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Abstract Number: 0838

T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis
Abstract Number: 0839

Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species
Abstract Number: 0840

Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation
Abstract Number: 0841

CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model
Abstract Number: 0842

mTOR Signaling Pathway Blockade and Rab4 Expression Affects Metabolism of Lupus T Cells
Abstract Number: 0843

Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Abstract Number: 0844

Rab4A Regulates Glomerulonephritis and Tryptophan Metabolism in Sle1.2.3. Lupus-prone Mice via Recycling of CD98
Abstract Number: 0845

Hematopoietic Specific Deficiency of Rho Kinase Attenuates Neutrophil NETosis and UVB-induced Skin Inflammation
Abstract Number: 0846

MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Abstract Number: 0847

Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Abstract Number: 0848

Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].